Wells Fargo's analyst Brandon Couillard has reduced the price target for Mesa Labs (MLAB, Financial) from $120 to $100. The decision comes as the company's Q4 revenues matched expectations, but adjusted EBITDA fell short by approximately $2 million due to higher-than-anticipated bonus accruals. This shortfall has led to a significant drop in MLAB's share price. Wells Fargo has retained an Underweight rating on the stock, citing the weakness in Q4 profit margins as a primary concern.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Mesa Laboratories Inc (MLAB, Financial) is $135.00 with a high estimate of $160.00 and a low estimate of $100.00. The average target implies an upside of 29.02% from the current price of $104.64. More detailed estimate data can be found on the Mesa Laboratories Inc (MLAB) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Mesa Laboratories Inc's (MLAB, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Mesa Laboratories Inc (MLAB, Financial) in one year is $153.58, suggesting a upside of 46.78% from the current price of $104.635. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Mesa Laboratories Inc (MLAB) Summary page.
